Loading...

KMD

KMD

KAMADA LTD

(KMDA)

2025 6-K

Kamada Filing Update

31 Mar '26

FDA Approval Received

26 Mar '26

Dividend Payment Update

17 Mar '26

Dividend and Growth

11 Mar '26

Kamada Filing Update

4 Mar '26

Kamada Financial Guidance

7 Jan '26

Tender Extension

18 Dec '25

Shareholder Meeting Results

10 Dec '25

Clinical Trial Update

8 Dec '25

Amended Proxy Filing

2 Dec '25

Strong Performance Report

10 Nov '25

Clinical Trial Enrollment

4 Nov '25

Annual Meeting Announcement

23 Oct '25

Investor Conference Announc...

2 Sep '25

Strong Financial Growth

13 Aug '25

FDA Approval Received

11 Aug '25

Kamada Filing Update

6 Aug '25

Business Operations Confirmed

17 Jun '25

Strong Financial Results

14 May '25

Kamada Filing Update

7 May '25

Research Program Launch

5 May '25

Kamada Dividend Update

24 Mar '25

Plasma Collection Expansion

19 Mar '25

Kamada Financial Update

5 Mar '25

Kamada Filing Update

26 Feb '25

Contract Announcement

22 Jan '25

Financial Guidance Update

8 Jan '25

Annual General Meeting

11 Dec '24

Profitable Growth Update

13 Nov '24

Kamada Filing Update

6 Nov '24

Conference Presentation

4 Nov '24

Annual Meeting Notice

21 Oct '24

Plasma Expansion

23 Sep '24

Strong Financial Results

14 Aug '24

Earnings Announcement

7 Aug '24

Strong Financial Results

8 May '24

Kamada Updates

1 May '24

Strong Fiscal Performance

6 Mar '24

Earnings Announcement

28 Feb '24

External Links:

SEC

Kamada Ltd. announced a new comprehensive post-marketing research program for its product CYTOGAM on May 5, 2025. This filing is significant for the company as it relates to ongoing product evaluation and regulatory compliance.

AI Assistant

KAMADA LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.